Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Operations (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Cash from Operations for 7 consecutive years, with 264000.0 as the latest value for Q3 2025.

  • For Q3 2025, Cash from Operations rose 84.62% year-over-year to 264000.0; the TTM value through Sep 2025 reached 1375000.0, up 77.94%, while the annual FY2024 figure was 4333000.0, 79.6% up from the prior year.
  • Cash from Operations hit 264000.0 in Q3 2025 for Cyclerion Therapeutics, up from 503000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 360000.0 in Q4 2024 and bottomed at 14455000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 5496894.74, with a median of 6214000.0 recorded in 2023.
  • Year-over-year, Cash from Operations crashed 96.37% in 2022 and then soared 123.36% in 2024.
  • Cyclerion Therapeutics' Cash from Operations stood at 8630000.0 in 2021, then increased by 18.39% to 7043000.0 in 2022, then skyrocketed by 78.12% to 1541000.0 in 2023, then skyrocketed by 123.36% to 360000.0 in 2024, then plummeted by 173.33% to 264000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 264000.0, 503000.0, and 968000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.